TG Therapeutics jumps on 2026 revenue outlook, prelim 2025 sales beat

TG Therapeutics

14/01/2026 13:46

** Shares of drugmaker TG Therapeutics TGTX.O up about 10% at $30.64 premarket

** TGTX expects total revenue for 2026 in the range of $875 million to $900 million, compared with estimates of $895.63 million, according to data compiled by LSEG

** Expects total revenue for 2025 at $616 million, above analysts' estimates of $606.6 million

** TGTX expects 2025 U.S. sales of $594 million for its multiple sclerosis drug, Briumvi, up about 92% from a year earlier

** Jefferies analysts expect data for subcutaneous version of Briumvi, which is expected by the end of 2026, to be "a large inflection point"

** Shares fell marginally in 2025

(Reporting by Gnaneshwar Rajan in Bengaluru)

((Gnaneshwar.Rajan@thomsonreuters.com;))